Elevate Chicago · Policy & Education
Why Are We Okay With This?
A closer look at FDA approval, peptide access, compounding, and the growing debate over whether regulation protects innovation — or slows it down.
Red Dye No. 40 can be legally used in foods, drugs, and cosmetics. Meanwhile, many emerging compounds used or studied in longevity and regenerative medicine face significant restrictions despite strong consumer and clinician interest.
The part most people don’t realize
Red 40
FDA permits Red Dye No. 40 for use in foods, drugs, and cosmetics under its color additive regulations.
Vitamin C supplements
Dietary supplements generally do not go through FDA premarket approval for safety and effectiveness before being sold.
Most cosmetics
Most cosmetic products and ingredients can enter the market without FDA premarket approval, with certain exceptions such as color additives.
Compounded medications
Compounded drugs are not individually FDA-approved, even when they are legally prescribed and prepared by licensed pharmacies under federal and state rules.
Where peptides fit in
The current peptide debate centers on FDA compounding policy under Sections 503A and 503B of federal law. Compounds such as the ones below have become part of a broader policy discussion about whether certain peptides should be available through regulated compounding pathways.
Robert F. Kennedy Jr. has publicly voiced support for broader peptide access and has argued that excessive restriction can push consumers toward unregulated gray-market sources instead of licensed clinicians and pharmacies.
The question is not whether every peptide is proven.
The question is whether regulated medical access is safer than forcing demand underground.
The argument for a smarter middle ground
Emerging medicine does not need a free-for-all. It needs a framework that protects patients without making innovation impossible.
- Licensed clinicians
- Legitimate 503A/503B compounding pharmacies
- Identity, potency, purity, and sterility testing
- Patient-specific prescribing
- Informed consent
- Baseline and follow-up laboratory testing
- Adverse-event reporting
- Transparent data collection
Why the traditional approval pathway creates tension
Modern drug development is extraordinarily expensive. The FDA user fee for a new drug application requiring clinical data is itself measured in the millions of dollars, before accounting for research, manufacturing, trials, regulatory work, and commercialization.
That creates an economic reality: therapies that can support massive development budgets are easier to bring through the full approval pathway than inexpensive compounds with weaker patent protection or less commercial upside.
That does not mean unapproved compounds are automatically safe or effective. It does mean there is a legitimate policy question around whether the same path should be the only path.
Our position at Elevate Chicago
Regulate quality. Regulate safety. Regulate fraud.
But do not create a system where responsible physicians, regulated pharmacies, and informed patients are blocked from emerging therapies simply because a billion-dollar pharmaceutical pathway has not yet been completed.
Medicine moves forward by identifying signals, studying outcomes, improving protocols, and building evidence. The goal should be responsible access — not reckless access, and not blanket restriction.
Regulate it. Test it. Track it.
Don’t drive it underground.
Important: This page is for educational and policy discussion only. It is not medical advice and does not claim that any specific peptide or compounded therapy is FDA-approved, proven safe, or appropriate for any individual. Treatment decisions should be made by a licensed clinician based on applicable law, evidence, and the patient’s medical history.